The document discusses concepts related to meta-analysis including covariates, subgroup analysis, and meta-regression. It provides examples and questions related to analyzing trials of vitamin D supplementation and mortality in institutionalized elderly people. Maximum follow-up is identified as a study-level covariate. Subgroup analyses should be specified a priori, and meta-regressions on patient-level covariates can be valid if the association is biologically plausible.
The document is a quiz on key concepts in developing systematic reviews including key questions, stakeholders, and ensuring relevance and transparency. It covers topics like the role of key informants in providing context and ensuring key questions address real-world issues, and allowing public commentary on topic refinement to be a final check of relevance.
Observational studies should always be considered for inclusion in comparative effectiveness reviews. When deciding whether to include observational studies to assess benefits, reviewers should first determine if there are gaps in evidence from randomized controlled trials. When assessing harms, cohort and case-control studies should be routinely included. If gaps in trial evidence are identified, the review questions should be refocused to those gaps and observational studies addressing them should be included. Studies with high risk of confounding by indication bias are generally not suitable.
This document discusses study eligibility criteria for systematic reviews. It defines PICOTS as the key components to consider for criteria: Population, Intervention, Comparator, Outcome, Timing, and Setting. Study eligibility criteria should be determined before reviewing literature and applied consistently to avoid bias and ensure the reviewed studies can be appropriately compared. Well-constructed eligibility criteria based on PICOTS can help reviewers focus on the most relevant literature and answer the intended question.
This document discusses conducting a comprehensive literature search for a systematic review on the use of thrombectomy devices in acute coronary syndromes. It emphasizes the importance of understanding the topic thoroughly before designing search strategies, using precise search terms and multiple databases and searches to balance recall and precision, considering hand searching and grey literature, and transparently reporting the search process and results.
C3 - How Do We Use HTA and Real-World Evidence to Implement “Reassessments” E...Emilie Adams
The document discusses challenges in using real-world evidence and health technology assessment to effectively implement "reassessments" of healthcare interventions. It outlines a 5-step process: 1) develop research questions, 2) produce evidence, 3) review evidence, 4) use evidence to inform policy, and 5) use policy to change practice. Key challenges addressed are getting the right research question, building capacity to conduct analyses, ensuring evidence is reviewed in a timely manner, and whether recommendations will actually be used to inform decisions. The document emphasizes using evidence judiciously and only collecting more data if the value exceeds the cost.
The document provides an overview of the AGREE II tool for assessing clinical practice guidelines. It discusses the six domains of the AGREE II instrument which are used to evaluate guidelines. These domains contain a total of 23 items addressing scope and purpose, stakeholder involvement, rigor of development, clarity and presentation, applicability, and editorial independence. The document outlines how to use the AGREE II tool including scoring guidelines, considerations before assessment, and what each domain evaluates. It aims to guide users on properly applying the AGREE II instrument to appraise clinical practice guidelines in a reliable manner.
The document discusses concepts related to meta-analysis including covariates, subgroup analysis, and meta-regression. It provides examples and questions related to analyzing trials of vitamin D supplementation and mortality in institutionalized elderly people. Maximum follow-up is identified as a study-level covariate. Subgroup analyses should be specified a priori, and meta-regressions on patient-level covariates can be valid if the association is biologically plausible.
The document is a quiz on key concepts in developing systematic reviews including key questions, stakeholders, and ensuring relevance and transparency. It covers topics like the role of key informants in providing context and ensuring key questions address real-world issues, and allowing public commentary on topic refinement to be a final check of relevance.
Observational studies should always be considered for inclusion in comparative effectiveness reviews. When deciding whether to include observational studies to assess benefits, reviewers should first determine if there are gaps in evidence from randomized controlled trials. When assessing harms, cohort and case-control studies should be routinely included. If gaps in trial evidence are identified, the review questions should be refocused to those gaps and observational studies addressing them should be included. Studies with high risk of confounding by indication bias are generally not suitable.
This document discusses study eligibility criteria for systematic reviews. It defines PICOTS as the key components to consider for criteria: Population, Intervention, Comparator, Outcome, Timing, and Setting. Study eligibility criteria should be determined before reviewing literature and applied consistently to avoid bias and ensure the reviewed studies can be appropriately compared. Well-constructed eligibility criteria based on PICOTS can help reviewers focus on the most relevant literature and answer the intended question.
This document discusses conducting a comprehensive literature search for a systematic review on the use of thrombectomy devices in acute coronary syndromes. It emphasizes the importance of understanding the topic thoroughly before designing search strategies, using precise search terms and multiple databases and searches to balance recall and precision, considering hand searching and grey literature, and transparently reporting the search process and results.
C3 - How Do We Use HTA and Real-World Evidence to Implement “Reassessments” E...Emilie Adams
The document discusses challenges in using real-world evidence and health technology assessment to effectively implement "reassessments" of healthcare interventions. It outlines a 5-step process: 1) develop research questions, 2) produce evidence, 3) review evidence, 4) use evidence to inform policy, and 5) use policy to change practice. Key challenges addressed are getting the right research question, building capacity to conduct analyses, ensuring evidence is reviewed in a timely manner, and whether recommendations will actually be used to inform decisions. The document emphasizes using evidence judiciously and only collecting more data if the value exceeds the cost.
The document provides an overview of the AGREE II tool for assessing clinical practice guidelines. It discusses the six domains of the AGREE II instrument which are used to evaluate guidelines. These domains contain a total of 23 items addressing scope and purpose, stakeholder involvement, rigor of development, clarity and presentation, applicability, and editorial independence. The document outlines how to use the AGREE II tool including scoring guidelines, considerations before assessment, and what each domain evaluates. It aims to guide users on properly applying the AGREE II instrument to appraise clinical practice guidelines in a reliable manner.
The document discusses quantitative synthesis and meta-analysis methods. It defines key terms like effect measures, heterogeneity, and fixed and random effects models. It also covers combining data across studies, including calculating weighted averages and addressing issues like Simpson's paradox and heterogeneity that can impact meta-analyses. Worked examples are provided for binary outcomes, risk ratios, and calculating treatment effects from studies.
Meta Analysis of Medical Device Data Applications for Designing Studies and R...NAMSA
This document discusses meta-analysis and its uses in medical device research. Meta-analysis statistically combines findings from multiple studies to reach a stronger conclusion. It can improve estimates of a treatment's effects, resolve uncertain or contradictory evidence from individual studies, and allow for smaller clinical studies by drawing from existing evidence. There are two main types of meta-analysis: individual participant data uses raw data from each subject, while aggregate data meta-analysis (more common) analyzes summary results across studies.
This document is an interactive quiz on reporting comparative effectiveness reviews. It contains questions about the reporting process, with answers indicating that reporting is an integral part of the review, the complete search strategy should be included, accurate reporting helps interpretation, and guidelines like PRISMA can aid writing the report. The summary provides guidance on key elements for transparently reporting the results of a comparative effectiveness review.
The document provides an overview of the Agency for Healthcare Research and Quality's (AHRQ) Effective Health Care Program. It describes the program's goals of conducting comparative effectiveness research to inform healthcare decisions. It outlines the key players and their roles, including Evidence-based Practice Centers that conduct evidence syntheses, stakeholders that provide input, and dissemination of findings to patients and policymakers.
The document discusses the importance of including information on harmful effects when conducting systematic reviews in order to properly assess the balance of benefits and harms of interventions. It notes that data on adverse effects is often incomplete and of lower quality than data on effectiveness, and provides suggestions for how to search for, analyze, and synthesize this information to provide a more comprehensive assessment of medical treatments. Gaps and weaknesses in current data on adverse effects are identified, and guidance is provided on prioritizing reviews to fill these evidence gaps.
Recommendations on Evidence Needed to Support Measurement Equivalence between...CRF Health
Patient-reported outcomes (PROs) are the consequences of disease and/or its treatment
as reported by the patient. The importance of PRO measures in clinical trials for new drugs, biologic
agents, and devices was underscored by the release of the US Food and Drug Administration’s draft
guidance for industry titled "Patient-Reported Outcome Measures: Use in Medical Product Development
to Support Labeling Claims." The intent of the guidance was to describe how the FDA will evaluate the
appropriateness and adequacy of PRO measures used as effectiveness endpoints in clinical trials. In
response to the expressed need of ISPOR members for further clarification of several aspects of the draft
guidance, ISPOR’s Health Science Policy Council created three task forces, one of which was charged
with addressing the implications of the draft guidance for the collection of PRO data using electronic data
capture modes of administration (ePRO). The objective of this report is to present recommendations from
ISPOR’s ePRO Good Research Practices Task Force regarding the evidence necessary to support the
comparability, or measurement equivalence, of ePROs to the paper-based PRO measures from which
they were adapted.
Models of evaluation in educational technologyalsalmi
The document discusses different models for evaluating educational technology programs. It analyzes studies that evaluated continuing medical education web-based programs using Kirkpatrick's model of evaluation, which measures reaction, learning, behavior, and results. Many studies found improved learning outcomes and performance through pre-and post-testing. However, the findings suggest more research is needed to determine which web-based learning systems best enhance practice changes and impact patient health outcomes.
This document discusses a new drug development paradigm (NDDP) that aims to improve the efficiency and effectiveness of clinical drug development. It outlines several proposals that call for reforming the current drug development model, including using more modeling, adaptive trial designs, and integrating clinical trials into healthcare delivery systems. The NDDP proposes a more flexible framework with early patient/payer engagement, exploratory and confirmatory research phases using modern trial designs, and post-approval studies to establish relative value. Challenges for industry include conducting large simple trials, partnering to support more efficient trials, and having a clear evidentiary strategy tailored to different drug archetypes.
The cochrane library an introduction for rheumatologists - 17 feb 2014Tamara Rader
The Cochrane Library provides high-quality systematic reviews and other evidence to inform healthcare decisions. It contains six databases, including the Cochrane Database of Systematic Reviews which publishes Cochrane Reviews that synthesize medical studies. Cochrane Reviews follow a rigorous methodology to identify and analyze data from relevant studies to determine if interventions are effective. The goal is to provide reliable evidence to help patients, practitioners, and policymakers make informed choices about healthcare.
The document summarizes the Cochrane Database of Systematic Reviews, which contains over 3000 systematic reviews and 1700 protocols. The reviews primarily analyze randomized controlled trials to evaluate the effects of interventions in healthcare relating to prevention, treatment, rehabilitation, and more. The database includes reviews of alternative and natural treatments as well as English and non-English language trials.
A new method for valuing quality of life: Direct elicitation of personal util...Office of Health Economics
This document describes a new proposed method for directly eliciting personal utility functions to value health-related quality of life. The standard approach uses stated preference methods to value a subset of health states, but this has limitations. The new method would ask people directly about the relative importance of health dimensions and levels to construct individual utility functions. A study piloted this approach in the Netherlands and UK and found it to be acceptable. However, further work is needed to reduce burden and improve validation before it can be fully implemented and used to value other health outcome measures.
Emerging diagnostic technologies proving the clinical application through g...Lyssa Friedman
Next Generation Sequencing is an exciting new technology for diagnostics companies. But is it right for all products and for all companies? This presentation was delivered via Webinar for a IVD audience for Q1 Productions, March 25, 2014.
This document discusses quality assessment in systematic reviews. It states that quality assessment is required to interpret individual study results and grade the body of evidence. The key steps of quality assessment are identifying the study design, evaluating sources of bias, and rating quality based on freedom from bias. When choosing a quality assessment tool, the most important consideration is how well it covers sources of bias. When reporting quality assessment, systematic reviewers must describe the criteria, processes used, and how overall quality ratings were generated.
No, grading the strength of evidence is not the same as rating the quality of individual studies. Grading the strength of evidence involves assessing the body of evidence as a whole based on required domains of risk of bias, consistency, directness and precision of individual studies. Reviewers must understand these concepts, know the four required domains and discretionary domains that can be used, understand the different strength of evidence grades, and approaches for combining domain scores, such as the GRADE approach. Reviewers should reach consensus on scoring domains and the overall strength of evidence grade.
1. Operational research began in the 1930s to help optimize resource allocation for problems in defense, industry, education, and health services.
2. It uses scientific techniques to help policymakers and program managers review, redirect, and restructure programs to improve efficiency, effectiveness, and evidence-based decision making.
3. Some examples of operational research include optimizing tuberculosis screening and treatment, improving adherence to HIV/AIDS treatment, and evaluating new interventions through implementation research before scaling up programs.
This document discusses systematic reviews and meta-analyses. It provides information on Number Needed to Treat (NNT) and Number Needed to Harm (NNH). It also discusses how to set up a protocol for a systematic review, including determining study design, selection criteria, treatment arms and statistical considerations. The Cochrane Collaboration is mentioned as performing systematic reviews and meta-analyses to evaluate healthcare interventions.
The Cochrane Library is a collection of databases that provides high-quality, systematic reviews of the effects of healthcare interventions. It contains the Cochrane Database of Systematic Reviews, which summarizes conclusions about the effectiveness of interventions based on empirical evidence. Cochrane Reviews are considered the gold standard for systematic reviews because they are conducted to the highest methodological quality and updated regularly. The Cochrane Library also includes databases of controlled trials, reviews of other systematic reviews, methodology research, and economic evaluations to inform evidence-based healthcare decisions.
Developing the Reimbursement Story 2016-03-10Lyssa Friedman
The document discusses strategies for developing a reimbursement case for molecular diagnostic tests early in development. It emphasizes designing analytic and clinical validity studies to demonstrate test accuracy and association with clinical conditions. Clinical utility studies should show how test results impact patient management, outcomes, and healthcare costs. Randomized controlled trials provide the strongest evidence but alternative study designs like prospective observational studies and decision modeling may also support reimbursement. The goal is to generate evidence of a test's medical necessity from the intended patient population to achieve coverage and payment.
Safety and Affordabilty: Quantifying the impact of real-world evidenceZoe Mitchell
This document discusses assessing drug safety and risks using real-world evidence from outside of clinical trials. It begins by examining what can be learned about risks and safety from randomized controlled trials (RCTs), noting their limitations in detecting uncommon or long-term adverse events. The document then explores how real-life studies can help evaluate risks in pulmonary diseases by studying more diverse populations over longer time periods. Examples are provided of real-world studies assessing safety issues for COPD and asthma medications. Unmet needs in respiratory medicine are also identified where further safety data is required.
The document discusses quantitative synthesis and meta-analysis methods. It defines key terms like effect measures, heterogeneity, and fixed and random effects models. It also covers combining data across studies, including calculating weighted averages and addressing issues like Simpson's paradox and heterogeneity that can impact meta-analyses. Worked examples are provided for binary outcomes, risk ratios, and calculating treatment effects from studies.
Meta Analysis of Medical Device Data Applications for Designing Studies and R...NAMSA
This document discusses meta-analysis and its uses in medical device research. Meta-analysis statistically combines findings from multiple studies to reach a stronger conclusion. It can improve estimates of a treatment's effects, resolve uncertain or contradictory evidence from individual studies, and allow for smaller clinical studies by drawing from existing evidence. There are two main types of meta-analysis: individual participant data uses raw data from each subject, while aggregate data meta-analysis (more common) analyzes summary results across studies.
This document is an interactive quiz on reporting comparative effectiveness reviews. It contains questions about the reporting process, with answers indicating that reporting is an integral part of the review, the complete search strategy should be included, accurate reporting helps interpretation, and guidelines like PRISMA can aid writing the report. The summary provides guidance on key elements for transparently reporting the results of a comparative effectiveness review.
The document provides an overview of the Agency for Healthcare Research and Quality's (AHRQ) Effective Health Care Program. It describes the program's goals of conducting comparative effectiveness research to inform healthcare decisions. It outlines the key players and their roles, including Evidence-based Practice Centers that conduct evidence syntheses, stakeholders that provide input, and dissemination of findings to patients and policymakers.
The document discusses the importance of including information on harmful effects when conducting systematic reviews in order to properly assess the balance of benefits and harms of interventions. It notes that data on adverse effects is often incomplete and of lower quality than data on effectiveness, and provides suggestions for how to search for, analyze, and synthesize this information to provide a more comprehensive assessment of medical treatments. Gaps and weaknesses in current data on adverse effects are identified, and guidance is provided on prioritizing reviews to fill these evidence gaps.
Recommendations on Evidence Needed to Support Measurement Equivalence between...CRF Health
Patient-reported outcomes (PROs) are the consequences of disease and/or its treatment
as reported by the patient. The importance of PRO measures in clinical trials for new drugs, biologic
agents, and devices was underscored by the release of the US Food and Drug Administration’s draft
guidance for industry titled "Patient-Reported Outcome Measures: Use in Medical Product Development
to Support Labeling Claims." The intent of the guidance was to describe how the FDA will evaluate the
appropriateness and adequacy of PRO measures used as effectiveness endpoints in clinical trials. In
response to the expressed need of ISPOR members for further clarification of several aspects of the draft
guidance, ISPOR’s Health Science Policy Council created three task forces, one of which was charged
with addressing the implications of the draft guidance for the collection of PRO data using electronic data
capture modes of administration (ePRO). The objective of this report is to present recommendations from
ISPOR’s ePRO Good Research Practices Task Force regarding the evidence necessary to support the
comparability, or measurement equivalence, of ePROs to the paper-based PRO measures from which
they were adapted.
Models of evaluation in educational technologyalsalmi
The document discusses different models for evaluating educational technology programs. It analyzes studies that evaluated continuing medical education web-based programs using Kirkpatrick's model of evaluation, which measures reaction, learning, behavior, and results. Many studies found improved learning outcomes and performance through pre-and post-testing. However, the findings suggest more research is needed to determine which web-based learning systems best enhance practice changes and impact patient health outcomes.
This document discusses a new drug development paradigm (NDDP) that aims to improve the efficiency and effectiveness of clinical drug development. It outlines several proposals that call for reforming the current drug development model, including using more modeling, adaptive trial designs, and integrating clinical trials into healthcare delivery systems. The NDDP proposes a more flexible framework with early patient/payer engagement, exploratory and confirmatory research phases using modern trial designs, and post-approval studies to establish relative value. Challenges for industry include conducting large simple trials, partnering to support more efficient trials, and having a clear evidentiary strategy tailored to different drug archetypes.
The cochrane library an introduction for rheumatologists - 17 feb 2014Tamara Rader
The Cochrane Library provides high-quality systematic reviews and other evidence to inform healthcare decisions. It contains six databases, including the Cochrane Database of Systematic Reviews which publishes Cochrane Reviews that synthesize medical studies. Cochrane Reviews follow a rigorous methodology to identify and analyze data from relevant studies to determine if interventions are effective. The goal is to provide reliable evidence to help patients, practitioners, and policymakers make informed choices about healthcare.
The document summarizes the Cochrane Database of Systematic Reviews, which contains over 3000 systematic reviews and 1700 protocols. The reviews primarily analyze randomized controlled trials to evaluate the effects of interventions in healthcare relating to prevention, treatment, rehabilitation, and more. The database includes reviews of alternative and natural treatments as well as English and non-English language trials.
A new method for valuing quality of life: Direct elicitation of personal util...Office of Health Economics
This document describes a new proposed method for directly eliciting personal utility functions to value health-related quality of life. The standard approach uses stated preference methods to value a subset of health states, but this has limitations. The new method would ask people directly about the relative importance of health dimensions and levels to construct individual utility functions. A study piloted this approach in the Netherlands and UK and found it to be acceptable. However, further work is needed to reduce burden and improve validation before it can be fully implemented and used to value other health outcome measures.
Emerging diagnostic technologies proving the clinical application through g...Lyssa Friedman
Next Generation Sequencing is an exciting new technology for diagnostics companies. But is it right for all products and for all companies? This presentation was delivered via Webinar for a IVD audience for Q1 Productions, March 25, 2014.
This document discusses quality assessment in systematic reviews. It states that quality assessment is required to interpret individual study results and grade the body of evidence. The key steps of quality assessment are identifying the study design, evaluating sources of bias, and rating quality based on freedom from bias. When choosing a quality assessment tool, the most important consideration is how well it covers sources of bias. When reporting quality assessment, systematic reviewers must describe the criteria, processes used, and how overall quality ratings were generated.
No, grading the strength of evidence is not the same as rating the quality of individual studies. Grading the strength of evidence involves assessing the body of evidence as a whole based on required domains of risk of bias, consistency, directness and precision of individual studies. Reviewers must understand these concepts, know the four required domains and discretionary domains that can be used, understand the different strength of evidence grades, and approaches for combining domain scores, such as the GRADE approach. Reviewers should reach consensus on scoring domains and the overall strength of evidence grade.
1. Operational research began in the 1930s to help optimize resource allocation for problems in defense, industry, education, and health services.
2. It uses scientific techniques to help policymakers and program managers review, redirect, and restructure programs to improve efficiency, effectiveness, and evidence-based decision making.
3. Some examples of operational research include optimizing tuberculosis screening and treatment, improving adherence to HIV/AIDS treatment, and evaluating new interventions through implementation research before scaling up programs.
This document discusses systematic reviews and meta-analyses. It provides information on Number Needed to Treat (NNT) and Number Needed to Harm (NNH). It also discusses how to set up a protocol for a systematic review, including determining study design, selection criteria, treatment arms and statistical considerations. The Cochrane Collaboration is mentioned as performing systematic reviews and meta-analyses to evaluate healthcare interventions.
The Cochrane Library is a collection of databases that provides high-quality, systematic reviews of the effects of healthcare interventions. It contains the Cochrane Database of Systematic Reviews, which summarizes conclusions about the effectiveness of interventions based on empirical evidence. Cochrane Reviews are considered the gold standard for systematic reviews because they are conducted to the highest methodological quality and updated regularly. The Cochrane Library also includes databases of controlled trials, reviews of other systematic reviews, methodology research, and economic evaluations to inform evidence-based healthcare decisions.
Developing the Reimbursement Story 2016-03-10Lyssa Friedman
The document discusses strategies for developing a reimbursement case for molecular diagnostic tests early in development. It emphasizes designing analytic and clinical validity studies to demonstrate test accuracy and association with clinical conditions. Clinical utility studies should show how test results impact patient management, outcomes, and healthcare costs. Randomized controlled trials provide the strongest evidence but alternative study designs like prospective observational studies and decision modeling may also support reimbursement. The goal is to generate evidence of a test's medical necessity from the intended patient population to achieve coverage and payment.
Safety and Affordabilty: Quantifying the impact of real-world evidenceZoe Mitchell
This document discusses assessing drug safety and risks using real-world evidence from outside of clinical trials. It begins by examining what can be learned about risks and safety from randomized controlled trials (RCTs), noting their limitations in detecting uncommon or long-term adverse events. The document then explores how real-life studies can help evaluate risks in pulmonary diseases by studying more diverse populations over longer time periods. Examples are provided of real-world studies assessing safety issues for COPD and asthma medications. Unmet needs in respiratory medicine are also identified where further safety data is required.
The document summarizes discussions from the Respiratory Effectiveness Group's 2015 Winter Summit held in Rotterdam, Netherlands from January 22-24, 2015. Key topics discussed included maximizing the use of respiratory disease databases for research, identifying new data resources, and the work of the Small Airways Study Group and Adherence Working Group. Presentations were also given on extra-fine inhaled corticosteroids and the emerging area of asthma-COPD overlap syndrome.
This document discusses Denmark's national health registries and their use for epidemiological research. It notes that Denmark assigns unique personal identification numbers to all citizens, allowing accurate linkage between various health registries. This enables large population-based cohort studies with long-term follow up. The registries contain information on healthcare utilization, prescriptions, and diagnoses. Several studies are described that use the registries to study topics like MMR vaccination and autism, quality of diabetes care, and blood pressure control. Challenges with using registry data include ensuring validity of diagnoses and missing data. However, strengths include no selection bias, large sample sizes, and prospectively collected data.
The study aims to compare the effectiveness of different step 2 asthma management approaches in pre-school children using a retrospective cohort design. The primary outcome is asthma exacerbations over 1 year as defined by ATS/ERS criteria. Secondary outcomes include acute respiratory events, risk domain asthma control, and reliever medication use. Eligible children aged 5 or under will be identified from UK clinical databases based on wheezing episodes or oral steroid prescriptions in the prior year. They will be matched and compared based on initial step 2 treatment of either EF ICS, NEF ICS, LTRA, or SABA alone. Subgroup analyses are planned based on atopy and demographic factors. An exploratory analysis will also assess outcomes over
SNIIRAM: PRIMARY AND SECONDARY CARE RESOURCE USE IN FRANCEZoe Mitchell
This document summarizes information from the SNIIRAM database in France. It discusses:
- SNIIRAM is a national database containing medical claims data from primary, secondary, and tertiary care.
- It allows linkage of data between different levels of care to study patient pathways.
- Examples of studies using SNIIRAM data include analyzing inhaled corticosteroid use patterns in asthma patients, comparing effectiveness of allergen immunotherapy in children with rhinitis, and assessing montelukast's impact on asthma control in infants.
This document provides an overview and agenda for the 2015 REG Winter Summit. It begins with a welcome from David Price, the REG Chairman. It then reviews some of REG's accomplishments in 2014, including publishing papers in a supplement, having proposals accepted at conferences, and growing its network of collaborators and supporters. It discusses REG formalizing its structure with new committees and working groups. It highlights some of REG's research from 2014 focusing on asthma control and severity. It outlines plans and opportunities for REG in 2015, including sessions at respiratory conferences and completing current studies. It closes by welcoming attendees and looking forward to the opportunities to share ideas and strengthen relationships at the summit.
REG COPD Control Working Group Meeting 25/9/15Zoe Mitchell
- The document summarizes a COPD control working group meeting discussing two observational pilot studies in Spain validating the concept of COPD control.
- The first study compares changes in control status to changes in severity over 6 months. The second compares control status to respiratory symptoms.
- It also summarizes a UK database pilot study characterizing COPD patients by control status and its clinical implications using the Optimum Patient Care Research Database.
- The study found that only 3.19% of 2,788 COPD patients were considered controlled based on the defined criteria. Uncontrolled patients were more likely to experience exacerbations.
Using CPCSSN Data for Primary Care Research in CanadaZoe Mitchell
CPCSSN provides de-identified primary care data from across Canada for research purposes. It holds data on demographics, diagnoses, medications, lab results, and other clinical information on over 368,000 patients from 329 physicians. The data requires cleaning and standardization. Research opportunities include epidemiological studies, clinical effectiveness research, quality improvement studies, and examining associations. Researchers must submit a letter of intent outlining their study for approval before gaining access to the de-identified data.
This document summarizes a workshop on cost-effectiveness analysis for respiratory health technologies. The workshop objectives were to introduce cost-effectiveness modeling, discuss what can and cannot be done with these models, and review current evidence gaps. The document then summarizes a cost-effectiveness model developed for ivacaftor treatment of cystic fibrosis. The model found ivacaftor to be cost-effective compared to usual care. Key gaps in COPD and asthma cost-effectiveness studies were identified. Finally, forming a working group to address these evidence gaps through additional research was discussed.
REG Child Health Working Group Meeting 26/09/15Zoe Mitchell
This document provides details of a child health working group meeting, including the agenda, completed work, publication status, and a presentation on a comparative effectiveness study of extra-fine particle inhaled corticosteroids and alternative guideline-recommended step-up options in preschool children with asthma. The meeting will take place on September 26th in Amsterdam, chaired by Steve Turner, and will discuss a real-life MASCOT study, abstracts previously presented, the publication status of three papers, and a proposed comparative effectiveness study using the Optimum Patient Care Research Database to compare outcomes of different treatment approaches for preschool wheeze/asthma.
REG COPD Control Working Group MeetingZoe Mitchell
1. The REG COPD Control Working Group met on May 17th in Denver, Colorado to discuss plans to validate the concept of control in COPD through several research studies.
2. These included a non-interventional database study using the UK OPCRD, two Spanish pilot studies on changes in control versus severity and symptoms, and an international prospective study to validate the concept of control.
3. The group discussed objectives, timelines, and plans for implementation of these validation studies, as well as identifying new areas of research and disseminating results. The goal was to establish control as a valid concept that could help guide treatment decisions and motivate patients.
This document summarizes the agenda and key discussion points for several committee meetings taking place on September 26th in Amsterdam. The Research Review committee will discuss priorities for funding respiratory research studies in 2015/2016. They will also evaluate the process for soliciting and reviewing research ideas. The Accreditation committee will discuss accrediting researchers. The Manuscript Review committee will examine their publication process and output over the past year. Overall, the meetings aim to strategize how the organization can best support high-quality respiratory research through prioritizing ideas, funding studies, and disseminating results.
The document provides details about an upcoming annual general meeting for the Respiratory Effectiveness Group (REG). The meeting will take place on September 26th at the Wyndham Apollo Hotel in Amsterdam. David Price will chair the meeting, which will review REG's activities from 2013 to 2015 and look ahead to future opportunities. Some of the key accomplishments highlighted include establishing a global network of over 270 collaborators across 38 countries, running numerous research studies and task forces, publishing several papers and abstracts, and hosting successful summits in 2014 and 2015. The meeting aims to further develop REG's working groups and collaborative activities to generate real-world evidence that can guide clinical practice and policy.
Information System for the Enhancement of Research in Primary CareZoe Mitchell
This document describes SIDIAP, a database created in 2010 to promote primary care research using clinical data from electronic medical records of over 5.8 million patients in Catalonia, Spain. SIDIAP contains socio-demographic, clinical, prescription, and hospitalization data. It adds value through high population coverage, validated data, and symbiosis with health providers. Researchers can apply to use de-identified data for studies. Limitations include some unavailable variables, but improvements are being made. Examples of respiratory research include COPD prescription patterns and identifying gaps in alpha-1 antitrypsin deficiency diagnosis.
REG Biomarkers Working Group Meeting 26/09/15Zoe Mitchell
This document summarizes the agenda and discussion topics for a biomarker working group meeting on September 25th in Amsterdam. The group will discuss publishing updates, including a perspective article comparing NICE and GINA statements on FeNO and a review on the role of eosinophils in airways disease. They will also discuss potential research ideas using data from the Optimum Patient Care Research Database (OPCRD), including evaluating FeNO and eosinophils as predictors of outcomes in COPD. Additional biomarker data will be added to OPCRD, including IgE testing. The group agreed to further discuss selecting some initial research projects and set a date for their next meeting.
The meeting agenda provided an update on research activities and future plans for the REG Interstitial Lung Disease Working Group. David Price discussed ongoing and upcoming research studies, publications, and events. Future plans included a revised staffing structure, working group and council structure, and upcoming events in 2015 and 2016. The meeting also discussed driving quality standards, perspectives from industry supporters, and new funding opportunities like PCORI. An open discussion period concluded the meeting to gather feedback and ideas.
The document discusses strategies for developing a reimbursement case for molecular diagnostic tests early in development. It emphasizes designing analytic and clinical validity studies to demonstrate test accuracy and association with clinical conditions. Clinical utility studies should show how test results impact patient management, outcomes, and healthcare costs. Randomized controlled trials provide the strongest evidence but alternative study designs like prospective observational studies and decision modeling may also support reimbursement. The goal is to generate evidence of a test's medical necessity and value to payers from an early stage.
This document provides an overview of evidence-based periodontics. It discusses the need for evidence-based decision making to reduce variations in clinical practice. The advantages of an evidence-based approach are that it is objective, scientifically sound, patient-focused, and incorporates clinical expertise. The process of evidence-based decision making involves framing questions, searching for and appraising evidence from various sources and levels, evaluating outcomes, and implementing decisions. Key aspects include assessing evidence critically and avoiding changes to pre-established hypotheses.
Rising Importance of Health Economics & Outcomes ResearchCitiusTech
Health Economics & Outcomes Research (HE&OR) guides stakeholders to make informed decisions regarding patient access to drugs and services. This document highlights specific use cases for healthcare information technology that add value to HE&OR.
This document provides guidelines for publishing manuscripts in medical/dental journals. It discusses various types of manuscripts like case reports, case series, research articles, and systematic reviews. It explains guidelines for each type like CARE guidelines for case reports and CONSORT guidelines for clinical trials. It also discusses the peer review process, impact factor, indexing/abstracting of journals, and tips for manuscript acceptance. Overall, the document serves as a useful reference for authors to understand the publishing process and guidelines for improving the quality of their manuscripts.
Week 5 Lab 3· If you choose to download the software from http.docxcockekeshia
Week 5 Lab 3
· If you choose to download the software from http://www.easyphp.org, use the installation guide provided here to install the EasyPHP.
Lab 3: XAMPP and MySQL Setup
Due Week 5 and worth 75 points
· Install XAMPP and MySQL and take a screen shot that shows the MySQL prompt on your screen. (screen shot optional)
· Research the capabilities of MySQL.
Write a one to two (1-2) page paper in which you:
1. Describe your experiences related to your setup of MySQL. Include any difficulties or issues that you had encountered during the installation.
1. Based on your post-installation research, describe the main capabilities of MySQL.
1. Describe the approach that you would take to go from a conceptual or logical model that you created to the implementation of that database structure in MySQL. Determine the additional information that you will need to implement the database design in a database management system.
Your assignment must follow these formatting requirements:
. Be typed, double spaced, using Times New Roman font (size 12), with one-inch margins on all sides; citations and references must follow APA or school-specific format. Check with your professor for any additional instructions.
. Include a cover page containing the title of the assignment, the student’s name, the professor’s name, the course title, and the date. The cover page and the reference page are not included in the required assignment page length.
Research studies show thatevidence-based practice(EBP) leads to higher qual-
ity care, improved patient out-
comes, reduced costs, and greater
nurse satisfaction than traditional
approaches to care.1-5 Despite
these favorable findings, many
nurses remain inconsistent in their
implementation of evidence-based
care. Moreover, some nurses,
whose education predates the in-
clusion of EBP in the nursing cur-
riculum, still lack the computer
and Internet search skills neces-
sary to implement these practices.
As a result, misconceptions about
EBP—that it’s too difficult or too
time-consuming—continue to
flourish.
In the first article in this series
(“Igniting a Spirit of Inquiry: An
Essential Foundation for Evidence-
Based Practice,” November 2009),
we described EBP as a problem-
solving approach to the delivery
of health care that integrates the
best evidence from well-designed
studies and patient care data,
and combines it with patient
preferences and values and nurse
expertise. We also addressed the
contribution of EBP to improved
care and patient outcomes, de-
scribed barriers to EBP as well as
factors facilitating its implementa-
tion, and discussed strategies for
igniting a spirit of inquiry in clin-
ical practice, which is the founda-
tion of EBP, referred to as Step
Zero. (Editor’s note: although
EBP has seven steps, they are
numbered zero to six.) In this
article, we offer a brief overview
of the multistep EBP process.
Future articles will elaborate on
each of the EBP steps, using
the context provided by the
Cas.
This document describes the Continuous Update Project, a novel approach developed by the World Cancer Research Fund to systematically review mechanistic evidence on diet, nutrition, physical activity and cancer. The approach involves conducting systematic reviews and meta-analyses of both epidemiological and mechanistic studies to make judgements on causal relationships. It emphasizes reproducibility, predefined criteria, and reviews evidence separately from making judgements. The goal is to help identify causal links between exposures and cancer outcomes.
Strategy to incorporate pharmacoeconomics into pharmacotherapy Ravi Kumar Yadav
Pharmacoeconomics of the health care intervention is equally important like the safety and efficacy of drug. The various strategies are available to incorporate pharmacoeconomics into pharmacotherapy. The most popular strategies for applying pharmacoeconomics to assess the value of pharmaceutical products and services include using the results of published pharmacoeconomic studies, building economic models, and conducting pharmacoeconomic research.
The document discusses evidence-based practice (EBP) in nursing. It defines EBP as using the best available research evidence, clinical expertise, and patient values to make decisions about patient care. The document outlines the steps of EBP, which include asking questions, finding evidence, appraising evidence, applying it to practice, and assessing outcomes. It also discusses popular EBP models like the Johns Hopkins Nursing EBP model and the Iowa model. Barriers to EBP and its advantages are summarized as well.
Evidence-based practice (EBP) uses scientific evidence to determine the best practices. EBP emerged in the 1980s and started in England in the early 1990s. EBP involves using the best current evidence from research, clinical expertise, and patient preferences to make decisions about patient care. Implementing EBP requires finding and applying effective interventions through a systematic process. Barriers to EBP include lack of time, support, and research knowledge, but EBP can improve outcomes, consistency of care, and decision-making. Common models for EBP include the John Hopkins, Iowa, and Stetler models.
This document provides an overview of evidence-based practice (EBP) presented by Amritanshu Chanchal at Subharti Nursing College in Meerut. It defines EBP, discusses its components and key steps. The presentation covers asking questions using PICOT format, searching for evidence, critically appraising evidence, integrating evidence with clinical expertise and patient preferences, evaluating outcomes, and disseminating results. Models for EBP are also introduced, including the Iowa Model which outlines identifying triggers for change, determining organizational priority, and forming an interdisciplinary team to develop, evaluate and implement EBP changes.
How predictive models help Medicinal Chemists design better drugs_webinarAnn-Marie Roche
All scientific disciplines, including medicinal chemistry, are experiencing a revolution in unprecedented rates of data being generated and the subsequent analysis and exploitation of this data is increasingly fundamental to innovation. Using data to design better compounds is a challenge for Medicinal and Computational chemists.
The design of small-molecule drug candidates, encompassing characteristics such as potency, selectivity and ADMET (absorption, distribution, metabolism, excretion and toxicity) is a key factor in the success of clinical trials and computer-aided drug discovery/design methods have played a major role in the development of therapeutically important small molecules for over three decades. These methods are broadly classified as either structure-based or ligand-based.
In this webinar our expert Dr. Olivier Barberan will discuss ligand-based methods and he will cover the following:
How to use only ligand information to predict activity depending on its similarity/dissimilarity to previously known active ligands.
- Discuss ligand-based pharmacophores, molecular descriptors, and quantitative structure-activity relationships and important tools such as target/ligand databases necessary for successful implementation of various computer-aided drug discovery/design methods in a drug discovery campaign.
EBP Lecture by tefe.pptx.this power point were used for commonly health scien...MulugetaAbeneh1
The document discusses evidence-based practice (EBP) in nursing. It defines EBP as integrating the best research evidence, clinical expertise, and patient values. The document outlines the steps of EBP, including defining problems, finding and critically appraising evidence, and applying evidence to practice. It also discusses challenges of implementing EBP and using research findings to improve patient care.
· Reflect on the four peer-reviewed articles you critically apprai.docxVannaJoy20
· Reflect on the four peer-reviewed articles you critically appraised in Module 4, related to your clinical topic of interest and PICOT.
· Reflect on your current healthcare organization and think about potential opportunities for evidence-based change, using your topic of interest and PICOT as the basis for your reflection.
· Consider the best method of disseminating the results of your presentation to an audience.
The Assignment: (Evidence-Based Project)
Part 4: Recommending an Evidence-Based Practice Change
Create an 8- to 9-slide
narrated PowerPoint presentation in which you do the following:
· Briefly describe your healthcare organization, including its culture and readiness for change. (You may opt to keep various elements of this anonymous, such as your company name.)
· Describe the current problem or opportunity for change. Include in this description the circumstances surrounding the need for change, the scope of the issue, the stakeholders involved, and the risks associated with change implementation in general.
· Propose an evidence-based idea for a change in practice using an EBP approach to decision making. Note that you may find further research needs to be conducted if sufficient evidence is not discovered.
· Describe your plan for knowledge transfer of this change, including knowledge creation, dissemination, and organizational adoption and implementation.
· Explain how you would disseminate the results of your project to an audience. Provide a rationale for why you selected this dissemination strategy.
· Describe the measurable outcomes you hope to achieve with the implementation of this evidence-based change.
· Be sure to provide APA citations of the supporting evidence-based peer reviewed articles you selected to support your thinking.
· Add a lessons learned section that includes the following:
· A summary of the critical appraisal of the peer-reviewed articles you previously submitted
· An explanation about what you learned from completing the Evaluation Table within the Critical Appraisal Tool Worksheet Template (1-3 slides)
Zeinab Hazime
Nurs 6052
10/16/2022
Evaluation Table
Use this document to complete the
evaluation table requirement of the Module 4 Assessment,
Evidence-Based Project, Part 3A: Critical Appraisal of Research
Full
APA formatted citation of selected article.
Article #1
Article #2
Article #3
Article #4
Abraham, J., Kitsiou, S., Meng, A., Burton, S., Vatani, H., & Kannampallil, T.
(2020). Effects of CPOE-based medication ordering on outcomes: an overview of systematic reviews.
BMJ Quality & Safety, 29(10), 1-2.
Alanazi, A. (2020). The effect of computerized physician order entry on mortality rates in pediatric and neonatal care setting: Meta-analysis.
Informatics in Medicine
Unlocked, 19, 100308. https.
This document provides an overview of pharmacoeconomics and different types of economic evaluations used to compare the costs and benefits of healthcare programs and treatments. It defines pharmacoeconomics as identifying, measuring, and comparing the costs, risks, and benefits of alternative therapies to determine the best health outcome for resources invested. The document describes different types of economic evaluations including cost-of-illness evaluations, cost-minimization analysis, cost-benefit analysis, cost-effectiveness analysis, and cost-utility analysis. It provides examples of how each type of analysis can be applied and what units of measurement are used.
Adaptive Clinical Trials: Role of Modelling and Simulation SGS
To increase the efficiency of trials in drug development, optimal experimental design has been used to successfully optimize dose allocation and sampling schedules. Better incremental decisions in Phase I and II result in greater likelihood that the safety and efficacy of the right dose is being studied, for the right indication and in the right patient population. This approach involves a pre-planned adaptation of aspects of study design based on statistical and/or pharmacokinetic/pharmacodynamic (PK/PD) analysis. From a modelling and simulation (M&S) perspective, a prior understanding of concentration (dose)-efficacy and of concentration (dose)-toxicity relationship is needed.
Independent forces on the biomedical ecosystem is causing a convergence of care, quality measurement, and clinical research at the point of care. The presentation outlines some of the informatics implications of this convergence.
This document discusses managing healthcare costs in an era of healthcare reform. It includes an agenda for a presentation on the topic with sections on the state of analytics in healthcare, strategic profit and loss statements, use cases, best practices, sample reporting, and a question and answer session. It emphasizes that healthcare transformation requires integrated clinical, financial, administrative, and research data from across healthcare providers as well as analytics. It also notes that a lack of understanding of healthcare costs is a barrier to effective reimbursement approaches and that financial decision support is a top priority for providers.
Modeling results from Health Sciences dataJudson Chase
This document discusses strategies for using modeling and predictive analytics to reduce costs and improve efficiency in clinical trials. It provides examples of how modeling site activation and enrollment can help minimize delays and budget overruns. Risk-based monitoring is presented as another way to transition to more efficient monitoring. Savings projections are estimated for different therapeutic areas based on reducing clinical site monitoring costs from 30% to 3-15% of total costs. Overall, the document argues that predictive modeling approaches can help lower total costs of clinical trials through better planning, execution and oversight.
Abstract
To address the growing need for information on a therapeutic, besides information on safety and efficacy, and the increasing trend to extrapolate data from traditional randomized control trials (RCT’s) to influence clinical practice; an in-depth evaluation of the utility and practicability of RCT’s in influencing real-world clinical practice is evaluated. The pragmatic clinical trial (PCT) is discussed and introduced as a potentially viable means to influence clinical practice. The regulatory impact of this new adaptation is also explored. Concepts of study design, including concepts such as validity, generalizability, efficacy and effectiveness are discussed for both RCT’s and PCT’s.
1) A systematic review follows a strict methodology to identify and analyze relevant research on a focused question.
2) The process involves developing a protocol, searching multiple databases, screening studies, assessing bias, and synthesizing data.
3) Reporting guidelines like PRISMA ensure transparency and consistency in reporting systematic reviews.
Similar to Using the right E (Efficacy vs. Effectiveness) in Cost-Effectiveness / Affordability Assessments (20)
This document summarizes a meeting to discuss a proof of concept study on asthma-COPD overlap syndrome (ACOS) using electronic medical records. The study aims to test various smoking-related ACOS population definitions across databases to evaluate prevalence and agreement. The meeting reviewed results from a UK pilot study using one database and definitions based on clinical diagnoses over 2 years. Prevalence of ACOS varied from 8-32% depending on the source population. The meeting also discussed expanding the study to other eligible databases and characterizing clinical implications of different definitions.
Child Health Working Group and Small Airways Study Group Joint MeetingZoe Mitchell
This document provides an agenda and background information for a meeting of the Small Airways & Child Health Working Group. The agenda includes discussions on ongoing publications regarding chest nomenclature and a systematic review on ICS particle size. Presentations will cover pre-school asthma wheeze, new ideas for the group focusing on implications of ICS particle size on GERD and ACOS, and an oscillometry study overview. Background information is provided on the chest commentary and systematic review, including results showing extra-fine ICS have higher odds of asthma control and lower exacerbation rates than fine particle ICS. A proposed study on pre-school asthma will compare outcomes of EF ICS to NEF ICS, LTRA,
This document summarizes the agenda and attendees for an IPF/ILD working group meeting. The meeting will discuss developing and providing feedback on a questionnaire to characterize diagnostic practices for interstitial lung disease globally. Next steps that will be discussed include identifying national leads, translating and adapting the questionnaire for different regions, disseminating the questionnaire through working group networks, and addressing any missing global regions. The goal is to understand real-world diagnostic practices to inform the design of a future study on diagnostic agreement for IPF.
The document summarizes a meeting of the REG Collaborators at the ERS 2013 conference in Barcelona. The purpose of the meeting was to: 1) provide updates on current REG research activities and quality standards work; 2) generate ideas for new REG activities, including addressing guidelines; and 3) allow collaborators to share information on other projects. The agenda included presentations on ongoing asthma and COPD studies, quality standards highlights, working with guidelines, and an open ideas session for collaborators to discuss other initiatives. The meeting concluded by welcoming new REG collaborators from over 20 countries.
This document provides a summary of the Respiratory Effectiveness Group (REG) Collaborators' Meeting held at the 2013 European Respiratory Society Congress in Barcelona. The meeting agenda included updates on current REG activities like publications, research studies, and quality standards. Presentations were given on new data from studies on asthma and COPD phenotypes, smoking cessation, and validating real-life asthma endpoints. There was also discussion of developing standards for real-life research, engaging with guidelines, and new initiatives from collaborators. The research update highlighted studies on asthma control and adherence, oral steroid burden in refractory asthma, and predicting asthma risk.
Real Time Research in a Singapore Public Primary Care InstitutionZoe Mitchell
This document summarizes opportunities and challenges for real-time research in Singapore public primary care institutions. It provides an overview of the Singapore healthcare system and SingHealth Polyclinics' (SHP) role in primary care. SHP has integrated electronic health records and databases that can be used for research. However, challenges include integrating different databases, ensuring data access compliance, limited staff research capacity, and competing for research grants. The future includes staff database training, streamlining data access processes while complying with privacy laws, configuring systems to facilitate data mining, and establishing collaborations to expand SHP's research capacity.
This document discusses maximizing patient outcomes in respiratory care. It outlines the founding principles of the Respiratory Effectiveness Group (REG), which aims to better integrate real-world evidence from sources like observational studies and pragmatic trials into clinical practice guidelines. Currently, guidelines are often based primarily on randomized controlled trials, which have limitations and may not generalize to most patients. The document calls for considering a diversity of evidence and tailoring care to individual patient needs and characteristics. It also discusses how databases could help achieve more personalized care by providing real-world data on topics like disease prevalence, treatments, and outcomes across different healthcare systems.
Ron Dandurand presented at the Respiratory Effectiveness Group Summit in Lyon, France on April 15, 2016. His objectives were to prove the non-inferiority of spirometry compared to oscillometry, raise reasonable doubt that spirometry should be abandoned, and present a novel approach to spirometry analysis. He discussed the history and advantages/disadvantages of spirometry versus oscillometry. While oscillometry provides more data points, it is not fair to directly compare the two without accounting for their different information levels. Spirometry, if analyzed beyond typical indices, may be able to approximate small airway function tests and detect disease at earlier stages.
Validation of Real-World Thoracic CT Scanes for Quantitative Analysis of COPDZoe Mitchell
This study evaluated the reproducibility of quantitative CT (QCT) metrics of emphysema using clinical CT scans from multiple centers. The study found that QCT metrics like low attenuation area (LAA) and lung density (LD) were reproducible across different scanners when corrected for actual lung volume. Metrics were more reproducible when corrected for measured total lung capacity (TLC) than predicted TLC. Contrast media was found to alter QCT metrics in a predictable way such that contrast and non-contrast scans could be compared using correction factors. Validating these findings in other cohorts and understanding the lung volume changes with contrast media were identified as important future directions.
Utilising real-world evidence to achieve precision medicine in COPDZoe Mitchell
This document discusses precision medicine approaches to tailoring COPD management to individual patient needs and phenotypes. It reviews current guidelines for COPD pharmacotherapy and how to optimize therapy for the specific patient. It provides an overview of treatable traits and phenotypes in COPD and examples of targeting treatment based on a patient's profile, such as using ICS for an eosinophilic phenotype. The document also discusses two case scenarios - one involving a patient with recurrent exacerbations and how to determine the best treatment approach, and another involving optimizing therapy for a returning patient.
An overview of the work and initial results of the REG-EAACI Taskforce assessing the quality of literature in the field of real-world respiratory medicine.
REG PCORI Grant Planning Meeting 26/09/15Zoe Mitchell
The document outlines an agenda for a planning meeting between the Respiratory Effectiveness Group (REG) and the Patient-Centered Outcomes Research Institute (PCORI) to discuss potential comparative effectiveness research collaborations. Key items on the agenda include aligning the missions of REG and PCORI, discussing what comparative effectiveness research entails, engaging stakeholders, and generating ideas for potential research topics that could be funded through PCORI. The meeting aims to identify topics of interest to both organizations that incorporate patient-centered outcomes research.
NAVIGATING THE HORIZONS OF TIME LAPSE EMBRYO MONITORING.pdfRahul Sen
Time-lapse embryo monitoring is an advanced imaging technique used in IVF to continuously observe embryo development. It captures high-resolution images at regular intervals, allowing embryologists to select the most viable embryos for transfer based on detailed growth patterns. This technology enhances embryo selection, potentially increasing pregnancy success rates.
Travel vaccination in Manchester offers comprehensive immunization services for individuals planning international trips. Expert healthcare providers administer vaccines tailored to your destination, ensuring you stay protected against various diseases. Conveniently located clinics and flexible appointment options make it easy to get the necessary shots before your journey. Stay healthy and travel with confidence by getting vaccinated in Manchester. Visit us: www.nxhealthcare.co.uk
The biomechanics of running involves the study of the mechanical principles underlying running movements. It includes the analysis of the running gait cycle, which consists of the stance phase (foot contact to push-off) and the swing phase (foot lift-off to next contact). Key aspects include kinematics (joint angles and movements, stride length and frequency) and kinetics (forces involved in running, including ground reaction and muscle forces). Understanding these factors helps in improving running performance, optimizing technique, and preventing injuries.
- Video recording of this lecture in English language: https://youtu.be/Pt1nA32sdHQ
- Video recording of this lecture in Arabic language: https://youtu.be/uFdc9F0rlP0
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Pictorial and detailed description of patellar instability with sign and symptoms and how to diagnose , what investigations you should go with and how to approach with treatment options . I have presented this slide in my 2nd year junior residency in orthopedics at LLRM medical college Meerut and got good reviews for it
After getting it read you will definitely understand the topic.
STUDIES IN SUPPORT OF SPECIAL POPULATIONS: GERIATRICS E7shruti jagirdar
Unit 4: MRA 103T Regulatory affairs
This guideline is directed principally toward new Molecular Entities that are
likely to have significant use in the elderly, either because the disease intended
to be treated is characteristically a disease of aging ( e.g., Alzheimer's disease) or
because the population to be treated is known to include substantial numbers of
geriatric patients (e.g., hypertension).
These lecture slides, by Dr Sidra Arshad, offer a simplified look into the mechanisms involved in the regulation of respiration:
Learning objectives:
1. Describe the organisation of respiratory center
2. Describe the nervous control of inspiration and respiratory rhythm
3. Describe the functions of the dorsal and respiratory groups of neurons
4. Describe the influences of the Pneumotaxic and Apneustic centers
5. Explain the role of Hering-Breur inflation reflex in regulation of inspiration
6. Explain the role of central chemoreceptors in regulation of respiration
7. Explain the role of peripheral chemoreceptors in regulation of respiration
8. Explain the regulation of respiration during exercise
9. Integrate the respiratory regulatory mechanisms
10. Describe the Cheyne-Stokes breathing
Study Resources:
1. Chapter 42, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 36, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 13, Human Physiology by Lauralee Sherwood, 9th edition
The skin is the largest organ and its health plays a vital role among the other sense organs. The skin concerns like acne breakout, psoriasis, or anything similar along the lines, finding a qualified and experienced dermatologist becomes paramount.
Using the right E (Efficacy vs. Effectiveness) in Cost-Effectiveness / Affordability Assessments
1. R. Brett McQueen, PhD
Health Economist and Head of Statistics
Research in Real Life (RiRL)/Observational & Pragmatic Research Institute (OPRI)
Adjunct Assistant Professor
University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences
Using the right ‘E’
(E-fficacy vs. E-ffectiveness) in cost-
effectiveness/affordability assessments
2. ISPOR Real-World Task Force
• In 2007, the International Society for Pharmacoeconomics and Outcomes Research
(ISPOR) Real-World Data Task Force published a statement in support of using real-
world data for coverage and reimbursement decisions
• Defined as economic, clinical, or patient-centered data NOT derived from efficacy
randomized controlled trials (RCTs)
• Pragmatic trials, registries, administrative data, health surveys, electronic records, etc.
• Task force called for efficacy and effectiveness to be used to achieve the “fourth
hurdle,” demonstration of cost-effectiveness to gain coverage and reimbursement*
2
*Garrison LP Jr, Neumann PJ, Erickson P, Marshall D, Mullins CD. Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task
Force report. Value Health 2007;10:326–335.
3. Does the drug work and provide good value for money?
Randomized Controlled Trials (RCTs)
Coverage and Reimbursement bodies:
(i.e. Public and Private Payers)
Hurdle 4
Cost-Effectiveness
Regulatory Bodies: (i.e. US Food and Drug Administration,
European Medicines Agency)
Hurdles 1–3
Safety, Efficacy, Production
RCT-Informed
Best Available
Evidence
Trial-Based CEA Model-Based CEA
Can the drug be used safely?
Can the drug work?
Can it be produced to high quality?
End User: Clinicians and Patients
Campbell JD, McQueen RB, Briggs A. The “E” in Cost-Effectiveness Analyses: A Case Study of Omalizumab Efficacy and Effectiveness for Cost-Effectiveness Analysis Evidence. Ann Am Thorac Soc. 2014 Feb; 11 Suppl 2: S105-11.
4. Efficacy versus effectiveness data for cost-effectiveness studies
• Cost-effectiveness using efficacy
• Potential value of treatment tested in ideal environment (e.g., artificially enhanced
adherence, protocol-driven resource utilization)
• “Piggyback” study or model forecasting trial results
• Cost-effectiveness using effectiveness data
• Potential value relevant to decision-makers and patients*
• Modeling with real-world evidence (e.g., adherence-adjusted treatment effects,
real-world resource utilization)
• Each can address different yet equally important questions
• “Bounds” of evidence for adoption or rejection of a technology§
*Callahan KP, Bridges JF. Using comparative effectiveness research to inform-decision making: is there a role of economic evaluation? Journal of Comparative Effectiveness Research; 1(4), 299-301 (2012).
§ Campbell JD, McQueen RB, Briggs A. The “E” in Cost-Effectiveness Analyses: A Case Study of Omalizumab Efficacy and Effectiveness for Cost-Effectiveness Analysis Evidence. Ann Am Thorac Soc. 2014 Feb; 11 Suppl
2: S105-11.
5. CEA Steps
1.Define the cost-effectiveness objective, state the perspective of the analysis that will
determine what costs are relevant, select the alternative intervention(s), select the
study design
2.Define and measure the components of cost (Ci) and effect (Ei) by alternative
intervention,
3.Compute the incremental cost-effectiveness ratio,
4.Conduct sensitivity and/or uncertainty analyses,
5.Communicate findings and their limitations.
6. Omalizumab CEA Case Study: Cost-Efficacy versus Cost-
Effectiveness: Is There a Difference?
• Compare and contrast two European omalizumab cost-effectiveness
decision-analytic models:
• One drawing on data from explanatory RCT evidence (Dewilde and colleagues)
• “cost-efficacy” of omalizumab from the Swedish payer perspective
• €56,091 per QALY gained
• One drawing on data from pragmatic, observational studies (van Nooten and
colleagues)
• cost-effectiveness of omalizumab from the Netherlands payer perspective
• €38,371 per QALY gained
Campbell JD, McQueen RB, Briggs A. The “E” in Cost-Effectiveness Analyses: A Case Study of Omalizumab Efficacy and Effectiveness for Cost-Effectiveness Analysis Evidence. Ann Am Thorac Soc. 2014 Feb; 11 Suppl 2: S105-11.
7. Discussion
• Why the continued resistance/slow uptake of using effectiveness data, especially in model-
based cost-effectiveness analyses?
• Time lag between regulatory approval and availability of data from routine clinical practice
• Entrenched positions on the hierarchy of evidence
• Continue educating decision makers on the benefits of effectiveness data for cost-
effectiveness analyses
• Adhere to best practices (eg, ISPOR) or accepted value-based frameworks for cost-effectiveness
research
• Transparency of model technique and results
• Cost-effectiveness and broadly decision analysis do not fit into hierarchy of evidence
• Synthesis of multiple sources of evidence
• Accept that the interpretation of evidence requires judgment*
*Sir Michael Rawlins. De testimonio: on the evidence for decisions about the use of therapeutic interventions. Lancet 2008; 372: 2152-61